Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients with Active Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523
TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.
Treatment with 100 mg of guselkumab Q4W and Q8W resulted in improvements in multiple domains of PsA. These improvements were maintained through 1 year in both TNFi-naive and TNFi-experienced populations. A consistent and positive safety profile was observed in both TNFi populations and was consistent with the guselkumab safety profile established for PsA and psoriasis.
Keywords:
